Efficacy and Safety of DOACs for the Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis
Thrombosis and Haemostasis · 2026-08 · 126 (08) · 832-842
DOI: 10.1055/a-2788-3034 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 27.01.2026. Verfasst von Andrea Boccatonda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bolo…. Hauptthemen laut MEDLINE: Anticoagulants, Factor Xa Inhibitors, Venous Thromboembolism, Venous Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Direct oral anticoagulants (DOACs) are increasingly used for superficial vein thrombosis (SVT), yet evidence remains limited. This systematic review and meta-analysis synthesizes all available data on the efficacy and safety of DOACs in SVT. A systematic search identified randomized and observational studies enrolling adults with acute SVT treated with DOACs. Primary efficacy outcomes were venous thromboembolism (VTE: deep vein thrombosis or pulmonary embolism) and SVT recurrence/extension. Safety outcomes included major and clinically relevant non-major bleeding (CRNMB). Six studies (n = 2,040; 602 DOAC-treated patients) met the inclusion criteria. Compared with fondaparinux, DOACs showed comparable short-term efficacy for VTE prevention (pooled risk ratio [RR] 0.93, 95% CI 0.44–1.99) and similar rates of SVT recurrence (RR 1.30, 95% CI 0.65–2.62). Versus placebo, rivaroxaban reduced recurrence by approximately 80% (RR 0.20, 95% CI 0.03–1.35). In the pooled safety analysis including four studies, DOACs were associated with a 65% relative risk reduction in major or CRNMB compared with fondaparinux or low-molecular-weight heparin (RR 0.35, 95% CI 0.15–0.83; I 2 = 0%). In the TROLL registry (n = 229; 74% DOAC), no major bleeding occurred among DOAC users, while 5-year cumulative VTE and SVT recurrence rates were each 15.9%. Certainty of evidence was moderate for efficacy and high for safety. DOACs demonstrate efficacy comparable to fondaparinux and an excellent safety profile in SVT, supporting their use as a practical oral alternative. Long-term data indicate persistent thrombotic risk, suggesting potential benefit of extended low-dose prophylaxis in selected high-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy.
- Department of Medicine, General Medicine and Thrombotic and Hemorrhagic Diseases Unit, University Hospital of Padova, Padova, Italy.
Zitieren
APA
Boccatonda, A., Brighenti, A., Simion, C., Simioni, P., & Campello, E. (2026). Efficacy and Safety of DOACs for the Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 126(08), 832-842. https://doi.org/10.1055/a-2788-3034
Vancouver
Boccatonda A, Brighenti A, Simion C, Simioni P, Campello E. Efficacy and Safety of DOACs for the Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis. 2026;126(08):832-842. doi:10.1055/a-2788-3034
BibTeX
@article{Boccatonda2026,
author = {Boccatonda, Andrea and Brighenti, Alice and Simion, Chiara and Simioni, Paolo and Campello, Elena},
title = {Efficacy and Safety of DOACs for the Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis},
journal = {Thrombosis and Haemostasis},
year = {2026},
volume = {126},
number = {08},
pages = {832--842},
doi = {10.1055/a-2788-3034}
}
EUVIMED